Pharma & Biotech

The telehealth sector faces increasing regulatory scrutiny, and Hims & Hers Health, Inc. is making strategic moves to navigate these...

Biopharmaceutical firm Clearside Biomedical finds itself navigating turbulent financial waters as it implements a comprehensive strategic transformation. The company's latest...

Sana Biotechnology's stock is experiencing dramatic price swings that highlight investor uncertainty. Following a steep 19% decline over ten trading...

Pfizer's recent $7 billion acquisition of biotechnology firm Metsera has triggered a wave of market skepticism rather than celebration. The...

Exelixis has ignited investor enthusiasm by reporting quarterly results that significantly exceeded market forecasts, coupled with the announcement of a...

Xoma Royalty Corporation delivered a powerful financial performance in the third quarter of 2025, significantly exceeding analyst forecasts with a...

Intellia Therapeutics is confronting one of its most severe market downturns following a cascade of negative developments that have severely...

Pharmaceutical leader Eli Lilly is making another substantial financial commitment, continuing its aggressive expansion through a major new partnership. This...

Baxter International Inc. finds its equity trading near annual lows as the medical technology company contends with a confluence of...

Natera's latest quarterly earnings report has sent its stock on a volatile ride, with investors responding enthusiastically to dramatically raised...